BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roberts LR, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, Heimbach JK, Murad MH, Mohammed K. Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. Hepatology 2018;67:401-21. [PMID: 28859233 DOI: 10.1002/hep.29487] [Cited by in Crossref: 199] [Cited by in F6Publishing: 173] [Article Influence: 49.8] [Reference Citation Analysis]
Number Citing Articles
1 Aggarwal A, Horwitz JK, Dolan D, Kamath A, Lewis S, Facciuto M, Grewal P, Fiel MI, Schiano T, Facciuto ME. Hypo-vascular hepatocellular carcinoma and liver transplantation: Morphological characteristics and implications on outcomes. J Surg Oncol 2019;120:1112-8. [PMID: 31486087 DOI: 10.1002/jso.25700] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Nadarevic T, Giljaca V, Colli A, Fraquelli M, Casazza G, Miletic D, Štimac D; Cochrane Hepato-Biliary Group. Computed tomography for the diagnosis of hepatocellular carcinoma in chronic advanced liver disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013362] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Liu Q, Li J, Liu F, Yang W, Ding J, Chen W, Wei Y, Li B, Zheng L. A radiomics nomogram for the prediction of overall survival in patients with hepatocellular carcinoma after hepatectomy. Cancer Imaging 2020;20:82. [PMID: 33198809 DOI: 10.1186/s40644-020-00360-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Evangelista EB, Kwee SA, Sato MM, Wang L, Rettenmeier C, Xie G, Jia W, Wong LL. Phospholipids are A Potentially Important Source of Tissue Biomarkers for Hepatocellular Carcinoma: Results of a Pilot Study Involving Targeted Metabolomics. Diagnostics (Basel) 2019;9:E167. [PMID: 31671805 DOI: 10.3390/diagnostics9040167] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Marks RM, Masch WR, Chernyak V. LI-RADS: Past, Present, and Future, From the AJR Special Series on Radiology Reporting and Data Systems. American Journal of Roentgenology 2021;216:295-304. [DOI: 10.2214/ajr.20.24272] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Vermersch M, Mulé S, Chalaye J, Galletto Pregliasco A, Emsen B, Amaddeo G, Monnet A, Stemmer A, Baranes L, Laurent A, Leroy V, Itti E, Luciani A. Impact of the 18F-FDG-PET/MRI on Metastatic Staging in Patients with Hepatocellular Carcinoma: Initial Results from 104 Patients. J Clin Med 2021;10:4017. [PMID: 34501465 DOI: 10.3390/jcm10174017] [Reference Citation Analysis]
7 Jiang HY, Chen J, Xia CC, Cao LK, Duan T, Song B. Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. World J Gastroenterol 2018; 24(22): 2348-2362 [PMID: 29904242 DOI: 10.3748/wjg.v24.i22.2348] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 11.8] [Reference Citation Analysis]
8 Xie S, Zhang Y, Chen J, Jiang T, Liu W, Rong D, Sun L, Zhang L, He B, Wang J. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI? Abdom Radiol (NY) 2022;47:596-607. [PMID: 34773467 DOI: 10.1007/s00261-021-03339-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Qureshi A, Michel M, Lerner J, Dasanu CA. Evolving therapeutic strategies for advanced hepatocellular carcinoma. Expert Opin Pharmacother 2021;:1-12. [PMID: 34252328 DOI: 10.1080/14656566.2021.1953473] [Reference Citation Analysis]
10 Varol Fİ. Pediatric Hepatocellular Carcinoma. J Gastrointest Cancer 2020;51:1169-75. [PMID: 32856229 DOI: 10.1007/s12029-020-00494-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Rastogi A. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma. World J Gastroenterol 2018; 24(35): 4000-4013 [PMID: 30254404 DOI: 10.3748/wjg.v24.i35.4000] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
12 Bashir MR, Horowitz JM, Kamel IR, Arif-Tiwari H, Asrani SK, Chernyak V, Goldstein A, Grajo JR, Hindman NM, Kamaya A, McNamara MM, Porter KK, Solnes LB, Srivastava PK, Zaheer A, Carucci LR; Expert Panel on Gastrointestinal Imaging. ACR Appropriateness Criteria® Chronic Liver Disease. J Am Coll Radiol 2020;17:S70-80. [PMID: 32370979 DOI: 10.1016/j.jacr.2020.01.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Chernyak V, Fowler KJ, Heiken JP, Sirlin CB. Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS): Use of Gadoxetate Disodium and LI-RADS. J Magn Reson Imaging 2019;49:1236-52. [DOI: 10.1002/jmri.26540] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
14 Yoo J, Lee JM. Diagnostic Value of High Frame Rate Contrast-enhanced Ultrasonography and Post-processing Contrast Vector Imaging for Evaluation of Focal Liver Lesions: A Feasibility Study. Ultrasound Med Biol 2020;46:2254-64. [PMID: 32546409 DOI: 10.1016/j.ultrasmedbio.2020.05.001] [Reference Citation Analysis]
15 Dong SY, Yang YT, Wang WT, Zhu S, Sun W, Zeng MS, Rao SX. Hepatobiliary phase images of gadoxetic acid-enhanced MRI may improve accuracy of predicting the size of hepatocellular carcinoma at pathology. Acta Radiol 2022;63:734-42. [PMID: 33969700 DOI: 10.1177/02841851211014194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Li N, Jiang Y, Plantefève R, Michaud F, Nosrati Z, Tremblay C, Saatchi K, Häfeli UO, Kadoury S, Moran G, Joly F, Martel S, Soulez G. Magnetic Resonance Navigation for Targeted Embolization in a Two-Level Bifurcation Phantom. Ann Biomed Eng 2019;47:2402-15. [PMID: 31290038 DOI: 10.1007/s10439-019-02317-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Park SH, Kim B, Kim SY, Choi SJ, Huh J, Kim HJ, Kim KW, Lee SS. Characterizing Computed Tomography-Detected Arterial Hyperenhancing-Only Lesions in Patients at Risk of Hepatocellular Carcinoma: Can Non-Contrast Magnetic Resonance Imaging Be Used for Sequential Imaging? Korean J Radiol 2020;21:280-9. [PMID: 32090520 DOI: 10.3348/kjr.2019.0447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Rich NE, Singal AG. Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines? Hepatology 2022;75:740-53. [PMID: 34923659 DOI: 10.1002/hep.32284] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Chandrapalan S, Bannaga A, Weidner A, Hitchins MP, Arasaradnam RP. A systematic review and meta-analysis: the diagnostic accuracy of methylated SEPTIN9 for the detection of hepatocellular carcinoma and the clinical evaluation of its use in combination with other surveillance modalities. Scand J Gastroenterol 2021;:1-8. [PMID: 34957898 DOI: 10.1080/00365521.2021.2020331] [Reference Citation Analysis]
20 Chen X, Li M, Guo R, Liu W, Li J, Zong X, Chen Q, Wang J. The diagnostic performance of contrast-enhanced CT versus extracellular contrast agent-enhanced MRI in detecting hepatocellular carcinoma: direct comparison and a meta-analysis. Abdom Radiol (NY) 2022;47:2057-70. [PMID: 35312822 DOI: 10.1007/s00261-022-03484-7] [Reference Citation Analysis]
21 Lee YT, Tran BV, Wang JJ, Liang IY, You S, Zhu Y, Agopian VG, Tseng HR, Yang JD. The Role of Extracellular Vesicles in Disease Progression and Detection of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3076. [PMID: 34203086 DOI: 10.3390/cancers13123076] [Reference Citation Analysis]
22 Ren A, Zhao P, Yang D, Du J, Wang Z, Yang Z. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017: LI-RADS v2018 of MRI for Diagnosing HCC. J Magn Reson Imaging 2019;50:746-55. [DOI: 10.1002/jmri.26640] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 11.3] [Reference Citation Analysis]
23 Chen H, Teng M, Zhang H, Liang X, Cheng H, Liu G. Advanced radionuclides in diagnosis and therapy for hepatocellular carcinoma. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.03.079] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Morisco F, Camera S, Guarino M, Tortora R, Cossiga V, Vitiello A, Cordone G, Caporaso N, Di Costanzo GG; Italian Liver Cancer (ITA.LI.CA) group. Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case-control study. Oncotarget 2018;9:17483-90. [PMID: 29707122 DOI: 10.18632/oncotarget.24756] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
25 Millet JD, Kamaya A, Choi HH, Dahiya N, Murphy PM, Naveed MZ, O’boyle M, Parra LA, Perez MG, Pirmoazen AM, Rodgers SK, Wasnik AP, Maturen KE. ACR Ultrasound Liver Reporting and Data System: Multicenter Assessment of Clinical Performance at One Year. Journal of the American College of Radiology 2019;16:1656-62. [DOI: 10.1016/j.jacr.2019.05.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
26 Pelizzaro F, Soldà F, Cardin R, Imondi A, Sartori A, Penzo B, Sammarco A, Aliberti C, Vitale A, Cillo U, Farinati F. SCCA-IgM in hepatocellular carcinoma patients treated with transarterial chemoembolization: gender-related differences. Biomark Med 2020;14:855-67. [PMID: 32808827 DOI: 10.2217/bmm-2019-0564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Min JH, Kim JM, Kim YK, Kim H, Cha DI, Kang TW, Choi GS, Choi SY, Ahn S. EASL versus LI-RADS: Intra-individual comparison of MRI with extracellular contrast and gadoxetic acid for diagnosis of small HCC. Liver Int 2021. [PMID: 34242468 DOI: 10.1111/liv.15012] [Reference Citation Analysis]
28 Rich NE, Parikh ND, Singal AG. Overdiagnosis: An Understudied Issue in Hepatocellular Carcinoma Surveillance. Semin Liver Dis 2017;37:296-304. [PMID: 29272892 DOI: 10.1055/s-0037-1608775] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
29 Vernuccio F, Cannella R, Bartolotta TV, Galia M, Tang A, Brancatelli G. Advances in liver US, CT, and MRI: moving toward the future. Eur Radiol Exp 2021;5:52. [PMID: 34873633 DOI: 10.1186/s41747-021-00250-0] [Reference Citation Analysis]
30 He H, Zhang X, Du L, Ye M, Lu Y, Xue J, Wu J, Shuai X. Molecular imaging nanoprobes for theranostic applications. Adv Drug Deliv Rev 2022;186:114320. [PMID: 35526664 DOI: 10.1016/j.addr.2022.114320] [Reference Citation Analysis]
31 Cisneros-garza L, González-huezo M, Moctezuma-velázquez C, Ladrón de Guevara-cetina L, Vilatobá M, García-juárez I, Alvarado-reyes R, Álvarez-treviño G, Allende-pérez S, Bornstein-quevedo L, Calderillo-ruiz G, Carrillo-martínez M, Castillo-barradas M, Cerda-reyes E, Félix-leyva J, Gabutti-thomas J, Guerrero-ixtlahuac J, Higuera-de-la-tijera F, Huitzil-meléndez D, Kimura-hayama E, López-hernández P, Malé-velázquez R, Méndez-sánchez N, Morales-ruiz M, Ruíz-garcía E, Sánchez-ávila J, Torrecillas-torres L. The second Mexican consensus on hepatocellular carcinoma. Part I: Epidemiology and diagnosis. Revista de Gastroenterología de México (English Edition) 2022. [DOI: 10.1016/j.rgmxen.2021.10.009] [Reference Citation Analysis]
32 Chen VL, Sharma P. Role of Biomarkers and Biopsy in Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:577-90. [DOI: 10.1016/j.cld.2020.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
33 Wong K, Ozeki K, Kwong A, Patel BN, Kwo P. The effects of a transjugular intrahepatic portosystemic shunt on the diagnosis of hepatocellular cancer. PLoS One 2018;13:e0208233. [PMID: 30592722 DOI: 10.1371/journal.pone.0208233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
34 Colli A, Nadarević T, Miletić D, Giljaca V, Fraquelli M, Štimac D, Casazza G; Cochrane Hepato-Biliary Group. Abdominal ultrasound and alpha-fetoprotein for the diagnosis of hepatocellular carcinoma. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013346] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
35 Hirmas N, Leyh C, Sraieb M, Barbato F, Schaarschmidt BM, Umutlu L, Nader M, Wedemeyer H, Ferdinandus J, Rischpler C, Herrmann K, Costa PF, Lange CM, Weber M, Fendler WP. 68Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma. J Nucl Med 2021;62:1235-41. [PMID: 33509970 DOI: 10.2967/jnumed.120.257915] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Biscaglia F, Quarta S, Villano G, Turato C, Biasiolo A, Litti L, Ruzzene M, Meneghetti M, Pontisso P, Gobbo M. PreS1 peptide-functionalized gold nanostructures with SERRS tags for efficient liver cancer cell targeting. Materials Science and Engineering: C 2019;103:109762. [DOI: 10.1016/j.msec.2019.109762] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
37 Lubel JS, Roberts SK, Strasser SI, Thompson AJ, Philip J, Goodwin M, Clarke S, Crawford DH, Levy MT, Shackel N. Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. Med J Aust 2021;214:475-83. [PMID: 33314233 DOI: 10.5694/mja2.50885] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
38 Lee BC, Jeong YY, Heo SH, Kim HO, Park C, Shin SS, Cho SB, Koh YS. Gadoxetic Acid-Enhanced MRI Features for Predicting Treatment Outcomes of Early Hepatocellular Carcinoma (< 3 cm) After Transarterial Chemoembolization. Acad Radiol 2022:S1076-6332(21)00483-9. [PMID: 35151549 DOI: 10.1016/j.acra.2021.10.012] [Reference Citation Analysis]
39 Adeniji N, Dhanasekaran R. Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. Hepatol Commun 2021. [PMID: 34533885 DOI: 10.1002/hep4.1823] [Reference Citation Analysis]
40 Jones PD, Scheinberg AR, Muenyi V, Gonzalez-Diaz J, Martin PM, Kobetz E. Socioeconomic And Survival Differences Among Minorities With Hepatocellular Carcinoma In Florida. J Hepatocell Carcinoma 2019;6:167-81. [PMID: 31815112 DOI: 10.2147/JHC.S212401] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
41 Zeng Z, Ouyang J, Sun L, Zeng C, Zeng F, Wu S. Activatable Nanocomposite Probe for Preoperative Location and Intraoperative Navigation for Orthotopic Hepatic Tumor Resection via MSOT and Aggregation-Induced Near-IR-I/II Fluorescence Imaging. Anal Chem 2020;92:9257-64. [PMID: 32530263 DOI: 10.1021/acs.analchem.0c01596] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
42 Moctezuma-Velázquez C, Lewis S, Lee K, Amodeo S, Llovet JM, Schwartz M, Abraldes JG, Villanueva A. Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B. JHEP Rep 2021;3:100364. [PMID: 34712933 DOI: 10.1016/j.jhepr.2021.100364] [Reference Citation Analysis]
43 Wang G, Lu X, Du Q, Zhang G, Wang D, Wang Q, Guo X. Diagnostic value of the γ-glutamyltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist II in hepatitis B virus-related hepatocellular carcinoma. Sci Rep 2020;10:13519. [PMID: 32782270 DOI: 10.1038/s41598-020-70241-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Li FY, Li JG, Wu SS, Ye HL, He XQ, Zeng QJ, Zheng RQ, An C, Li K. An Optimal Ablative Margin of Small Single Hepatocellular Carcinoma Treated with Image-Guided Percutaneous Thermal Ablation and Local Recurrence Prediction Base on the Ablative Margin: A Multicenter Study. J Hepatocell Carcinoma 2021;8:1375-88. [PMID: 34815974 DOI: 10.2147/JHC.S330746] [Reference Citation Analysis]
45 Han Y, Jiang W, Wang Y, Zhao M, Li Y, Ren L. Serum long non-coding RNA SCARNA10 serves as a potential diagnostic biomarker for hepatocellular carcinoma. BMC Cancer 2022;22:431. [PMID: 35443674 DOI: 10.1186/s12885-022-09530-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Bousabarah K, Letzen B, Tefera J, Savic L, Schobert I, Schlachter T, Staib LH, Kocher M, Chapiro J, Lin M. Automated detection and delineation of hepatocellular carcinoma on multiphasic contrast-enhanced MRI using deep learning. Abdom Radiol (NY) 2021;46:216-25. [PMID: 32500237 DOI: 10.1007/s00261-020-02604-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 23.0] [Reference Citation Analysis]
47 Pascual S, Miralles C, Bernabé JM, Irurzun J, Planells M. Surveillance and diagnosis of hepatocellular carcinoma: A systematic review. World J Clin Cases 2019; 7(16): 2269-2286 [PMID: 31531321 DOI: 10.12998/wjcc.v7.i16.2269] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
48 Langenbach MC, Vogl TJ, Said G, Scholtz JE, Hammerstingl R, Gruber-Rouh T. Lipiodol as a Predictive Indicator for Therapy Response to Transarterial Chemoembolization of Hepatocellular Carcinoma. Cancer Biother Radiopharm 2021. [PMID: 33481646 DOI: 10.1089/cbr.2020.4137] [Reference Citation Analysis]
49 Yang JD. Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. Clin Mol Hepatol 2019;25:335-43. [PMID: 30924328 DOI: 10.3350/cmh.2019.0010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
50 Banerjee I, Fisher PB, Sarkar D. Astrocyte elevated gene-1 (AEG-1): A key driver of hepatocellular carcinoma (HCC). Adv Cancer Res 2021;152:329-81. [PMID: 34353442 DOI: 10.1016/bs.acr.2021.05.003] [Reference Citation Analysis]
51 Qin R, Li S, Qiu Y, Feng Y, Liu Y, Ding D, Xu L, Ma X, Sun W, Chen H. Carbonized paramagnetic complexes of Mn (II) as contrast agents for precise magnetic resonance imaging of sub-millimeter-sized orthotopic tumors. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-29586-w] [Reference Citation Analysis]
52 Schwarze V, Rübenthaler J, Marschner C, Fabritius MP, Rueckel J, Fink N, Puhr-Westerheide D, Gresser E, Froelich MF, Schnitzer ML, Große Hokamp N, Afat S, Staehler M, Geyer T, Clevert DA. Advanced Fusion Imaging and Contrast-Enhanced Imaging (CT/MRI-CEUS) in Oncology. Cancers (Basel) 2020;12:E2821. [PMID: 33007933 DOI: 10.3390/cancers12102821] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
53 Consul N, Menias CO, Lubner MG, Katabathina VS, Chahinian RA, Mansour J, Elsayes KM. A Review of Viral-Related Malignancies and the Associated Imaging Findings. AJR Am J Roentgenol 2020;214:W1-W10. [PMID: 31593515 DOI: 10.2214/AJR.19.21357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Aslam A, Kamath A, Spieler B, Maschiocchi M, Sabottke CF, Chernyak V, Lewis SC. Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents. Abdom Radiol (NY) 2021;46:3565-78. [PMID: 33856509 DOI: 10.1007/s00261-021-03076-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Geyer T, Rübenthaler J, Marschner C, von Hake M, Fabritius MP, Froelich MF, Huber T, Nörenberg D, Rückel J, Weniger M, Martens C, Sabel L, Clevert DA, Schwarze V. Structured Reporting Using CEUS LI-RADS for the Diagnosis of Hepatocellular Carcinoma (HCC)-Impact and Advantages on Report Integrity, Quality and Interdisciplinary Communication. Cancers (Basel) 2021;13:534. [PMID: 33572502 DOI: 10.3390/cancers13030534] [Reference Citation Analysis]
56 Gazelakis K, Majeed A, Kemp W, Di Muzio B, Gerstenmaier J, Cheung W, Roberts SK. Liver disease severity predicts carcinogenesis of dysplastic liver nodules in cirrhosis. Sci Rep 2021;11:20954. [PMID: 34697374 DOI: 10.1038/s41598-021-00474-5] [Reference Citation Analysis]
57 Meng J, Gu F, Fang H, Qu B. Elevated Serum S100A9 Indicated Poor Prognosis in Hepatocellular Carcinoma after Curative Resection. J Cancer 2019;10:408-15. [PMID: 30719134 DOI: 10.7150/jca.28409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
58 Schwarze V, Marschner C, Völckers W, Grosu S, Negrão de Figueiredo G, Rübenthaler J, Clevert DA. Diagnostic value of contrast-enhanced ultrasound versus computed tomography for hepatocellular carcinoma: a retrospective, single-center evaluation of 234 patients. J Int Med Res 2020;48:300060520930151. [PMID: 32529869 DOI: 10.1177/0300060520930151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
59 Asadpour V, Parker RA, Mayock PR, Sampson SE, Chen W, Wu B. Pancreatic cancer tumor analysis in CT images using patch-based multi-resolution convolutional neural network. Biomedical Signal Processing and Control 2021;68:102652. [DOI: 10.1016/j.bspc.2021.102652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
60 Chai Y, Li K, Zhang C, Chen S, Ma K. The short-term efficacy of no-touch radiofrequency ablation in treating cirrhosis-based small hepatocellular carcinoma. BMC Cancer 2019;19:497. [PMID: 31133001 DOI: 10.1186/s12885-019-5707-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
61 Nadarevic T, Colli A, Giljaca V, Fraquelli M, Casazza G, Manzotti C, Štimac D, Miletic D. Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2022;5:CD014798. [PMID: 35521901 DOI: 10.1002/14651858.CD014798.pub2] [Reference Citation Analysis]
62 Ludwig DR, Romberg EK, Fraum TJ, Rohe E, Fowler KJ, Khanna G. Diagnostic performance of Liver Imaging Reporting and Data System (LI-RADS) v2017 in predicting malignant liver lesions in pediatric patients: a preliminary study. Pediatr Radiol 2019;49:746-58. [DOI: 10.1007/s00247-019-04358-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
63 Taniai M. Alcohol and hepatocarcinogenesis. Clin Mol Hepatol 2020;26:736-41. [PMID: 33053943 DOI: 10.3350/cmh.2020.0203] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
64 Chen W, Fu M, Zhang C, Xing Q, Zhou F, Lin M, Dong X, Huang J, Lin S, Hong M, Zheng Q, Pan J. Deep Learning-Based Universal Expert-Level Recognizing Pathological Images of Hepatocellular Carcinoma and Beyond. Front Med 2022;9:853261. [DOI: 10.3389/fmed.2022.853261] [Reference Citation Analysis]
65 Osho A, Rich NE, Singal AG. Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response. Hepatoma Res 2020;6:55. [PMID: 32944652 DOI: 10.20517/2394-5079.2020.42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Orimo T, Kamiyama T, Kamachi H, Shimada S, Nagatsu A, Asahi Y, Sakamoto Y, Abo D, Taketomi A. Predictive value of gadoxetic acid enhanced magnetic resonance imaging for posthepatectomy liver failure after a major hepatectomy. J Hepatobiliary Pancreat Sci 2020;27:531-40. [DOI: 10.1002/jhbp.769] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
67 Vogl TJ, Mader C, Michalik S, Hammerstingl R, Koch V. [Small hepatocellular carcinoma : Diagnostics according to guidelines and established in the clinical setting]. Radiologe 2022. [PMID: 35037980 DOI: 10.1007/s00117-021-00965-6] [Reference Citation Analysis]
68 Kim DK, An C, Chung YE, Choi JY, Lim JS, Park MS, Kim MJ. Hepatobiliary versus Extracellular MRI Contrast Agents in Hepatocellular Carcinoma Detection: Hepatobiliary Phase Features in Relation to Disease-free Survival. Radiology 2019;293:594-604. [PMID: 31592730 DOI: 10.1148/radiol.2019190414] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
69 Wang SH, Han XJ, Du J, Wang ZC, Yuan C, Chen Y, Zhu Y, Dou X, Xu XW, Xu H, Yang ZH. Saliency-based 3D convolutional neural network for categorising common focal liver lesions on multisequence MRI. Insights Imaging 2021;12:173. [PMID: 34817732 DOI: 10.1186/s13244-021-01117-z] [Reference Citation Analysis]
70 Liang Y, Xu F, Guo Y, Lai L, Jiang X, Wei X, Wu H, Wang J. Diagnostic performance of LI-RADS for MRI and CT detection of HCC: A systematic review and diagnostic meta-analysis. Eur J Radiol. 2021;134:109404. [PMID: 33276248 DOI: 10.1016/j.ejrad.2020.109404] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
71 Zhang H, Deng L, Liu H, Mai S, Cheng Z, Shi G, Zeng H, Wu Z. Enhanced fluorescence/magnetic resonance dual imaging and gene therapy of liver cancer using cationized amylose nanoprobe. Materials Today Bio 2022. [DOI: 10.1016/j.mtbio.2022.100220] [Reference Citation Analysis]
72 Sevco TJ, Masch WR, Maturen KE, Mendiratta-Lala M, Wasnik AP, Millet JD. Ultrasound (US) LI-RADS: Outcomes of Category US-3 Observations. AJR Am J Roentgenol 2021;217:644-50. [PMID: 34259543 DOI: 10.2214/AJR.20.23447] [Reference Citation Analysis]
73 Wang M, Fu F, Zheng B, Bai Y, Wu Q, Wu J, Sun L, Liu Q, Liu M, Yang Y, Shen H, Kong D, Ma X, You P, Li X, Tian F. Development of an AI system for accurately diagnose hepatocellular carcinoma from computed tomography imaging data. Br J Cancer 2021. [PMID: 34365472 DOI: 10.1038/s41416-021-01511-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Nadarevic T, Giljaca V, Colli A, Fraquelli M, Casazza G, Miletic D, Štimac D. Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;10:CD013362. [PMID: 34611889 DOI: 10.1002/14651858.CD013362.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
75 Mu X, Zhong Y, Zhang X, Qu C, Chen S. Early Diagnosis Value of DCE-MRI Hemodynamic Parameters in Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-9. [DOI: 10.1155/2022/9556589] [Reference Citation Analysis]
76 Castello A, Lopci E. Imaging HCC treated with radioembolization: review of the literature and clinical examples of choline PET utility. Clin Transl Imaging 2020;8:377-92. [DOI: 10.1007/s40336-020-00384-y] [Reference Citation Analysis]
77 Chung JW, Yu J, Choi JM, Cho E, Kim JH, Chung J. Subtraction Images From Portal Venous Phase Gadoxetic Acid–Enhanced MRI for Observing Washout and Enhancing Capsule Features in LI-RADS Version 2018. American Journal of Roentgenology 2020;214:72-80. [DOI: 10.2214/ajr.18.20797] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
78 Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
79 Lennartz S, Große Hokamp N, Zäske C, Zopfs D, Bratke G, Glauner A, Maintz D, Persigehl T, Chang DH, Hickethier T. Virtual monoenergetic images preserve diagnostic assessability in contrast media reduced abdominal spectral detector CT. Br J Radiol 2020;93:20200340. [PMID: 32644824 DOI: 10.1259/bjr.20200340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 Khanna R, Verma SK. Pediatric hepatocellular carcinoma. World J Gastroenterol 2018; 24(35): 3980-3999 [PMID: 30254403 DOI: 10.3748/wjg.v24.i35.3980] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
81 Yang XW, Fu XH, Zhang YJ. Clinical and pathological characteristics of cholangiolocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2019; 27(18): 1114-1117 [DOI: 10.11569/wcjd.v27.i18.1114] [Reference Citation Analysis]
82 Li J, Wang J, Lei L, Yuan G, He S. The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies. Eur Radiol 2019;29:6519-28. [PMID: 31250172 DOI: 10.1007/s00330-019-06294-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
83 Li M, Tang Y, Wang D, Zhai X, Shen H, Zhong C, Yao M, Jin A, Zhou Z, Zhou S, Fan J, Ling CQ, Ling C. Sphingosine-1-phosphate transporter spinster homolog 2 is essential for iron-regulated metastasis of hepatocellular carcinoma. Mol Ther 2021:S1525-0016(21)00467-6. [PMID: 34547466 DOI: 10.1016/j.ymthe.2021.09.012] [Reference Citation Analysis]
84 Hu HT, Wang W, Chen LD, Ruan SM, Chen SL, Li X, Lu MD, Xie XY, Kuang M. Artificial intelligence assists identifying malignant versus benign liver lesions using contrast-enhanced ultrasound. J Gastroenterol Hepatol 2021. [PMID: 33880797 DOI: 10.1111/jgh.15522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
85 Semaan S, Vietti Violi N, Lewis S, Chatterji M, Song C, Besa C, Babb JS, Fiel MI, Schwartz M, Thung S, Sirlin CB, Taouli B. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid. Eur Radiol 2020;30:1020-30. [PMID: 31673837 DOI: 10.1007/s00330-019-06458-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
86 Fraquelli M, Nadarevic T, Giljaca V, Colli A, Miletic D, Štimac D, Casazza G; Cochrane Hepato-Biliary Group. Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in advanced chronic liver disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013483] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
87 Cheng JT, Tan NE, Volk ML. Utility of positron emission tomography-computed tomography scan in detecting residual hepatocellular carcinoma post treatment: Series of case reports. World J Gastrointest Oncol 2020; 12(3): 358-364 [PMID: 32206185 DOI: 10.4251/wjgo.v12.i3.358] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-50. [PMID: 29624699 DOI: 10.1002/hep.29913] [Cited by in Crossref: 1646] [Cited by in F6Publishing: 1401] [Article Influence: 411.5] [Reference Citation Analysis]
89 Gupta R, Kleinjans J, Caiment F. Identifying novel transcript biomarkers for hepatocellular carcinoma (HCC) using RNA-Seq datasets and machine learning. BMC Cancer 2021;21:962. [PMID: 34445986 DOI: 10.1186/s12885-021-08704-9] [Reference Citation Analysis]
90 Schwarze V, Marschner C, Völckers W, de Figueiredo GN, Rübenthaler J, Clevert DA. The diagnostic performance of contrast-enhanced ultrasound (CEUS) for evaluating hepatocellular carcinoma (HCC) juxtaposed to MRI findings; a retrospective single-center analysis of 292 patients. Clin Hemorheol Microcirc 2020;76:155-60. [PMID: 32925017 DOI: 10.3233/CH-209213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
91 Colquhoun SD. Hepatocellular carcinoma clinical update: Current standards and therapeutic strategies. Liver Research 2020;4:180-90. [DOI: 10.1016/j.livres.2020.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Rahmanuddin S, Korn R, Cridebring D, Borazanci E, Brase J, Boswell W, Jamil A, Cai W, Sabir A, Motarjem P, Koay E, Mitra A, Goel A, Ho J, Chung V, Von Hoff DD. Role of 3D Volumetric and Perfusion Imaging for Detecting Early Changes in Pancreatic Adenocarcinoma. Front Oncol 2021;11:678617. [PMID: 34568010 DOI: 10.3389/fonc.2021.678617] [Reference Citation Analysis]
93 Kim DW, Choi SH, Kim SY, Byun JH, Lee SS, Park SH, Kim KW. Diagnostic performance of MRI for HCC according to contrast agent type: a systematic review and meta-analysis. Hepatol Int 2020;14:1009-22. [DOI: 10.1007/s12072-020-10100-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
94 Gupta P, Soundararajan R, Patel A, Kumar-M P, Sharma V, Kalra N. Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis. J Hepatol 2021;75:108-19. [PMID: 33548385 DOI: 10.1016/j.jhep.2021.01.041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
95 Yamaoka K, Saitoh S, Kinowaki K, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Fukusato T, Kumada H. Clinicopathological assessment of steatohepatitic hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2021;:101799. [PMID: 34500120 DOI: 10.1016/j.clinre.2021.101799] [Reference Citation Analysis]
96 Tu H, Chen L, Lin J, Wang J. Liver Cancer Confirmation by Contrast‐Enhanced Ultrasound Coupled With Magnetic Resonance Imaging: Case Report of Liver Inflammation Misdiagnosed as Atypical Liver Cancer. J Ultrasound Med 2020;39:1453-7. [DOI: 10.1002/jum.15233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
97 Filippi L, Schillaci O, Bagni O. Recent advances in PET probes for hepatocellular carcinoma characterization. Expert Review of Medical Devices 2019;16:341-50. [DOI: 10.1080/17434440.2019.1608817] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
98 Nadarevic T, Colli A, Giljaca V, Fraquelli M, Casazza G, Manzotti C, Štimac D, Miletic D; Cochrane Hepato-Biliary Group. Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd014798] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
99 Kim HI, Jang JK, Lim J, Chang S, An J, Kang HJ, Song GW, Lee SG, Kim SY, Shim JH. Hepatocyte-Specific Magnetic Resonance Imaging-Based Assessment of Indeterminate Hepatic Nodules in the Liver Transplant Evaluation of Patients With Cirrhosis. Liver Transpl 2020;26:359-69. [PMID: 31756026 DOI: 10.1002/lt.25684] [Reference Citation Analysis]
100 Saraiya N, Yopp AC, Rich NE, Odewole M, Parikh ND, Singal AG. Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy. Aliment Pharmacol Ther. 2018;48:127-137. [PMID: 29851093 DOI: 10.1111/apt.14823] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
101 Elmohr MM, Chernyak V, Sirlin CB, Elsayes KM. Liver Imaging Reporting and Data System Comprehensive Guide: MR Imaging Edition. Magn Reson Imaging Clin N Am 2021;29:375-87. [PMID: 34243924 DOI: 10.1016/j.mric.2021.05.012] [Reference Citation Analysis]
102 Barsoum I, Elgohary MN, Bassiony MAA. Lipocalin-2: A novel diagnostic marker for hepatocellular carcinoma. Cancer Biomark 2020;28:523-8. [PMID: 32568173 DOI: 10.3233/CBM-190084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
103 Liu JL, Bao D, Xu ZL, Zhuge XJ. Clinical value of contrast-enhanced computed tomography (CECT) combined with contrast-enhanced ultrasound (CEUS) for characterization and diagnosis of small nodular lesions in liver. Pak J Med Sci 2021;37:1843-8. [PMID: 34912405 DOI: 10.12669/pjms.37.7.4306] [Reference Citation Analysis]
104 Vernuccio F, Cannella R, Meyer M, Choudhoury KR, Gonzáles F, Schwartz FR, Gupta RT, Bashir MR, Furlan A, Marin D. LI-RADS: Diagnostic Performance of Hepatobiliary Phase Hypointensity and Major Imaging Features of LR-3 and LR-4 Lesions Measuring 10-19 mm With Arterial Phase Hyperenhancement. AJR Am J Roentgenol 2019;213:W57-65. [PMID: 31039012 DOI: 10.2214/AJR.18.20979] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
105 Cheng N, Ren Y, Zhou J, Zhang Y, Wang D, Zhang X, Chen B, Liu F, Lv J, Cao Q, Chen S, Du H, Hui D, Weng Z, Liang Q, Su B, Tang L, Han L, Chen J, Shao C. Deep Learning-Based Classification of Hepatocellular Nodular Lesions on Whole-Slide Histopathologic Images. Gastroenterology 2022:S0016-5085(22)00155-X. [PMID: 35202643 DOI: 10.1053/j.gastro.2022.02.025] [Reference Citation Analysis]
106 Zhou J, Yang W, Zhang S, He X, Lin J, Zhou T, Li Y, Wang G, Chen J. Diagnostic value of angiopoietin-like protein 2 for CHB-related hepatocellular carcinoma. Cancer Manag Res 2019;11:7159-69. [PMID: 31534368 DOI: 10.2147/CMAR.S217170] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
107 Yoon JH, Lee JM, Lee YJ, Lee KB, Han JK. Added Value of sequentially performed gadoxetic acid-enhanced liver MRI for the diagnosis of small (10-19 mm) or atypical hepatic observations at contrast-enhanced CT: A prospective comparison. J Magn Reson Imaging 2019;49:574-87. [PMID: 30102433 DOI: 10.1002/jmri.26199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
108 Bäumler W, Wiggermann P, Lürken L, Dollinger M, Stroszczynski C, Beyer LP, Schicho A. Early Detection of Local Tumor Progression after Irreversible Electroporation (IRE) of a Hepatocellular Carcinoma Using Gd-EOB-DTPA-Based MR Imaging at 3T. Cancers (Basel) 2021;13:1595. [PMID: 33808336 DOI: 10.3390/cancers13071595] [Reference Citation Analysis]
109 Srinivasan S, Dasgupta A, Chatterjee A, Baheti A, Engineer R, Gupta T, Murthy V. The Promise of Magnetic Resonance Imaging in Radiation Oncology Practice in the Management of Brain, Prostate, and GI Malignancies. JCO Glob Oncol 2022;8:e2100366. [PMID: 35609219 DOI: 10.1200/GO.21.00366] [Reference Citation Analysis]
110 Teng W, Liu YC, Jeng WJ, Su CW. Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. Cancers (Basel) 2021;13:1729. [PMID: 33917345 DOI: 10.3390/cancers13071729] [Reference Citation Analysis]
111 Gupta M, Gabriel H, Miller FH. Role of Imaging in Surveillance and Diagnosis of Hepatocellular Carcinoma. Gastroenterology Clinics of North America 2018;47:585-602. [DOI: 10.1016/j.gtc.2018.04.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
112 Petrasek J, Singal AG, Rich NE. Harms of hepatocellular carcinoma surveillance. Curr Hepatol Rep 2019;18:383-9. [PMID: 33214987 DOI: 10.1007/s11901-019-00488-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
113 Zhou JM, Wang T, Zhang KH. AFP-L3 for the diagnosis of early hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2021;100:e27673. [PMID: 34713864 DOI: 10.1097/MD.0000000000027673] [Reference Citation Analysis]
114 Yoon JH, Chang W, Lee ES, Lee SM, Lee JM. Double Low-Dose Dual-Energy Liver CT in Patients at High-Risk of HCC: A Prospective, Randomized, Single-Center Study. Invest Radiol 2020;55:340-8. [PMID: 31917765 DOI: 10.1097/RLI.0000000000000643] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
115 Greiser J, Weigand W, Freesmeyer M. Metal-Based Complexes as Pharmaceuticals for Molecular Imaging of the Liver. Pharmaceuticals (Basel) 2019;12:E137. [PMID: 31527492 DOI: 10.3390/ph12030137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
116 Tamaki N, Higuchi M, Kurosaki M, Kirino S, Osawa L, Watakabe K, Wang W, Okada M, Shimizu T, Takaura K, Takada H, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Enomoto N, Izumi N. Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct‐acting antivirals. J Viral Hepat 2019;26:893-9. [DOI: 10.1111/jvh.13103] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
117 Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 2021;156:463.e1-463.e30. [PMID: 33461840 DOI: 10.1016/j.medcli.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
118 Hill CE, Biasiolli L, Robson MD, Grau V, Pavlides M. Emerging artificial intelligence applications in liver magnetic resonance imaging. World J Gastroenterol 2021; 27(40): 6825-6843 [PMID: 34790009 DOI: 10.3748/wjg.v27.i40.6825] [Reference Citation Analysis]
119 Ludwig DR, Fraum TJ, Cannella R, Ballard DH, Tsai R, Naeem M, LeBlanc M, Salter A, Tsung A, Shetty AS, Borhani AA, Furlan A, Fowler KJ. Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018. Abdom Radiol (NY) 2019;44:2116-32. [PMID: 30798397 DOI: 10.1007/s00261-019-01948-x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 13.0] [Reference Citation Analysis]
120 Duan F, Wang YY, Xu DG, Shi J, Chen LY, Cui L, Bai YH, Xu Y, Yuan J, Chang C. Feasibility of terahertz imaging for discrimination of human hepatocellular carcinoma. World J Gastrointest Oncol 2019; 11(2): 153-160 [PMID: 30788041 DOI: 10.4251/wjgo.v11.i2.153] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
121 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases: Marrero et al. Hepatology 2018;68:723-50. [DOI: 10.1002/hep.29913] [78495111110.1002/hep.29913','', '1948-5182')">Reference Citation Analysis]
122 Rimola J, Darnell A, Belmonte E, Sapena V, Caparroz C, Llarch N, Reig M, Forner A, Bruix J, Ayuso C. Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid. Eur Radiol 2020;30:6694-701. [DOI: 10.1007/s00330-020-07039-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
123 Rimola J, Sapena V, Brancatelli G, Darnell A, Forzenigo L, Mähringer-Kunz A, Paisant A, Renzulli M, Schima W, Terraz S, Valls C, Wagner M, Ayuso C, Vilgrain V, Reig M, Ronot M. Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria. Hepatology 2022. [PMID: 35349760 DOI: 10.1002/hep.32494] [Reference Citation Analysis]
124 Min JH, Kim JM, Kim YK, Cha DI, Kang TW, Kim H, Choi GS, Choi S, Ahn S. Magnetic Resonance Imaging With Extracellular Contrast Detects Hepatocellular Carcinoma With Greater Accuracy Than With Gadoxetic Acid or Computed Tomography. Clinical Gastroenterology and Hepatology 2020;18:2091-2100.e7. [DOI: 10.1016/j.cgh.2019.12.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
125 Du Y, Ma X, Wang D, Wang Y, Zhang T, Bai L, Liu Y, Chen S. Identification of heterogeneous nuclear ribonucleoprotein as a candidate biomarker for diagnosis and prognosis of hepatocellular carcinoma. J Gastrointest Oncol 2021;12:2361-76. [PMID: 34790398 DOI: 10.21037/jgo-21-468] [Reference Citation Analysis]
126 Lee SW, Lee TY, Yang SS, Tong CF, Yeh HZ, Chang CS. Sorafenib-Related Adverse Events in Predicting the Early Radiologic Responses of Hepatocellular Carcinoma. Gastroenterology Res 2019;12:16-20. [PMID: 30834030 DOI: 10.14740/gr1109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
127 An C, Lee CH, Byun JH, Lee MH, Jeong WK, Choi SH, Kim DY, Lim YS, Kim YS, Kim JH, Choi MS, Kim MJ. Intraindividual Comparison between Gadoxetate-Enhanced Magnetic Resonance Imaging and Dynamic Computed Tomography for Characterizing Focal Hepatic Lesions: A Multicenter, Multireader Study. Korean J Radiol 2019;20:1616-26. [PMID: 31854149 DOI: 10.3348/kjr.2019.0363] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
128 Peng Z, Cao G, Hou Q, Li L, Ying S, Sun J, Zhou G, Zhou J, Zhang X, Ji W, Yu Z, Li T, Zhu D, Hu W, Ji J, Du H, Shi C, Guo X, Fang J, Han J, Gu W, Xie X, Sun Z, Xu H, Wu X, Hu T, Huang J, Hu H, Zheng J, Luo J, Chen Y, Yu W, Shao G. The Comprehensive Analysis of Efficacy and Safety of CalliSpheres® Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A Multiple-Center, Cohort Study. Oncol Res 2020;28:249-71. [PMID: 31856933 DOI: 10.3727/096504019X15766663541105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
129 Nan Y, Xu X, Gao Y, Wang R, Li W, Yang M, Liu L, Duan Z, Jia J, Wei L, Zhuang H; Chinese Society of Hepatology, Chinese Medical Association. Consensus on the secondary prevention of primary liver cancer. Hepatol Int 2021;15:1289-300. [PMID: 34846705 DOI: 10.1007/s12072-021-10259-7] [Reference Citation Analysis]
130 Kitamura S, Kai K, Nakamura M, Tanaka T, Ide T, Noshiro H, Sueoka E, Aishima S. Cytological Comparison between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma by Image Analysis Software Using Touch Smear Samples of Surgically Resected Specimens. Cancers 2022;14:2301. [DOI: 10.3390/cancers14092301] [Reference Citation Analysis]
131 Moura Cunha G, Chernyak V, Fowler KJ, Sirlin CB. Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:513-27. [PMID: 34104640 DOI: 10.2147/JHC.S268288] [Reference Citation Analysis]
132 Tietz E, Truhn D, Müller-Franzes G, Berres ML, Hamesch K, Lang SA, Kuhl CK, Bruners P, Schulze-Hagen M. A Radiomics Approach to Predict the Emergence of New Hepatocellular Carcinoma in Computed Tomography for High-Risk Patients with Liver Cirrhosis. Diagnostics (Basel) 2021;11:1650. [PMID: 34573991 DOI: 10.3390/diagnostics11091650] [Reference Citation Analysis]
133 Feng Z, Zhao H, Guan S, Wang W, Rong P. Diagnostic performance of MRI using extracellular contrast agents versus gadoxetic acid for hepatocellular carcinoma: A systematic review and meta‐analysis. Liver Int 2021;41:1117-28. [DOI: 10.1111/liv.14850] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
134 Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
135 Huang M, Zhao Q, Ye Z, Xu D, Tang S, Jiang T. Development of a novel melatonin-modified near-infrared fluorescent probe for in vivo hepatocellular carcinoma imaging. Anal Methods 2020;12:4556-61. [PMID: 33001063 DOI: 10.1039/d0ay01135e] [Reference Citation Analysis]
136 John BV, Aubuchon S, Dahman B, Konjeti VR, Heuman D, Hubert J, Thomas S, Deng Y, Solomon C, Sundaram LT, Love E, Singal AG, Tatum JL. Addition of [18 F]Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography to Cross-Sectional Imaging Improves Staging and Alters Management in Hepatocellular Carcinoma. Liver Transpl 2020;26:774-84. [PMID: 32128966 DOI: 10.1002/lt.25743] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
137 Seo N, Kim MS, Park MS, Choi JY, An C, Han K, Kim SU, Joo DJ, Kim MJ. Optimal criteria for hepatocellular carcinoma diagnosis using CT in patients undergoing liver transplantation. Eur Radiol 2019;29:1022-31. [PMID: 29974221 DOI: 10.1007/s00330-018-5557-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
138 Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, Kono Y, Do RK, Mitchell DG, Singal AG, Tang A, Sirlin CB. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology 2018;289:816-30. [PMID: 30251931 DOI: 10.1148/radiol.2018181494] [Cited by in Crossref: 212] [Cited by in F6Publishing: 196] [Article Influence: 53.0] [Reference Citation Analysis]
139 Woeste MR, Geller AE, Martin RCG 2nd, Polk HC Jr. Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer. Ann Surg Oncol 2021;28:1499-510. [PMID: 33393028 DOI: 10.1245/s10434-020-09414-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Du Y, Liu D, Du Y. Recent advances in hepatocellular carcinoma therapeutic strategies and imaging-guided treatment. J Drug Target 2021;:1-15. [PMID: 34727794 DOI: 10.1080/1061186X.2021.1999963] [Reference Citation Analysis]
141 Song D, Wang Y, Wang W, Cai J, Zhu K, Lv M, Gao Q, Zhou J, Fan J, Rao S, Wang M, Wang X. Using deep learning to predict microvascular invasion in hepatocellular carcinoma based on dynamic contrast-enhanced MRI combined with clinical parameters. J Cancer Res Clin Oncol. 2021 epub ahead of print. [PMID: 33839938 DOI: 10.1007/s00432-021-03617-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
142 Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, Landis C, Jun DW, Enomoto M, Ogawa E, Tsai PC, Le A, Liu M, Maeda M, Nguyen B, Ramrakhiani N, Henry L, Cheung R, Tamori A, Kumada T, Tanaka Y, Yu ML, Toyoda H, Nguyen MH. Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West. Hepatology 2020;71:1910-22. [PMID: 31610027 DOI: 10.1002/hep.30988] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 18.5] [Reference Citation Analysis]
143 Raatschen HJ. [Radiological diagnostic workup of liver tumors]. Internist (Berl) 2020;61:123-30. [PMID: 31919534 DOI: 10.1007/s00108-019-00724-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
144 Kleiner DE. Hepatocellular carcinoma: Liver biopsy in the balance. Hepatology 2018;68:13-5. [PMID: 29405373 DOI: 10.1002/hep.29831] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
145 Kim DW, Lee G, Kim SY, Ahn G, Lee JG, Lee SS, Kim KW, Park SH, Lee YJ, Kim N. Deep learning-based algorithm to detect primary hepatic malignancy in multiphase CT of patients at high risk for HCC. Eur Radiol 2021;31:7047-57. [PMID: 33738600 DOI: 10.1007/s00330-021-07803-2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
146 Yang X, Xiao J, Jiang L, Ran L, Fan Y, Zhang M, Xu Y, Yao C, An B, Yang Y, Yang C, Tian G, Zhang G, Zhang Y. A Multifunctional Vanadium-Iron-Oxide Nanoparticle Eradicates Hepatocellular Carcinoma via Targeting Tumor and Endothelial Cells. ACS Appl Mater Interfaces 2022. [PMID: 35698257 DOI: 10.1021/acsami.2c03474] [Reference Citation Analysis]
147 Vernuccio F, Cannella R, Gozzo C, Greco V, Midiri M, Furlan A, Tang A, Brancatelli G. Hepatic enhancement in cirrhosis in the portal venous phase: what are the differences between gadoxetate disodium and gadobenate dimeglumine? Abdom Radiol (NY) 2020;45:2409-17. [PMID: 32435849 DOI: 10.1007/s00261-020-02578-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
148 Rimola J, Davenport MS, Liu PS, Brown T, Marrero JA, McKenna BJ, Hussain HK. Diagnostic accuracy of MRI with extracellular vs. hepatobiliary contrast material for detection of residual hepatocellular carcinoma after locoregional treatment. Abdom Radiol (NY) 2019;44:549-58. [PMID: 30218239 DOI: 10.1007/s00261-018-1775-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
149 da Silva PH, Gomes MM, de Matos CAL, de Souza E Silva IS, Gonzalez AM, Torres US, Salazar GMM, D'Ippolito G. HCC Detection on Surveillance US: Comparing Focused Liver Protocol Using US LI-RADS Technical Guidelines to a General Complete Abdominal US Protocol. J Ultrasound Med 2021. [PMID: 33463734 DOI: 10.1002/jum.15637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Ren A, Du J, Yang D, Zhao P, Wang Z, Yang Z. The role of ancillary features for diagnosing hepatocellular carcinoma on CT: based on the Liver Imaging Reporting and Data System version 2017 algorithm. Clinical Radiology 2020;75:478.e25-35. [DOI: 10.1016/j.crad.2019.08.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Gündoğan C, Ergül N, Çakır MS, Kılıçkesmez Ö, Gürsu RU, Aksoy T, Çermik TF. 68Ga-PSMA PET/CT Versus 18F-FDG PET/CT for Imaging of Hepatocellular Carcinoma. Mol Imaging Radionucl Ther 2021;30:79-85. [PMID: 34082503 DOI: 10.4274/mirt.galenos.2021.92053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Caraiani C, Yi D, Petresc B, Dietrich C. Indications for abdominal imaging: When and what to choose? J Ultrason 2020;20:e43-54. [PMID: 32320166 DOI: 10.15557/JoU.2020.0008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
153 Singal AG, Lim JK, Kanwal F. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. Gastroenterology. 2019;156:2149-2157. [PMID: 30878469 DOI: 10.1053/j.gastro.2019.02.046] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 16.3] [Reference Citation Analysis]
154 Osawa L, Tamaki N, Kurosaki M, Kirino S, Watakabe K, Wang W, Okada M, Shimizu T, Higuchi M, Takaura K, Takada H, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Enomoto N, Izumi N. Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not α-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor. Int J Mol Sci 2020;21:E3640. [PMID: 32455631 DOI: 10.3390/ijms21103640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
155 Nahon P, Aubé C, Moga L, Chalaye J, Guiu B, Luciani A, Rode A, Ronot M, Seror O, Soussan M, Sutter O, Bourlière M, Bureau C, de Lédinghen V, Ganne-Carrié N. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PRIMARY MALIGNANT LIVER TUMOURS. Clin Res Hepatol Gastroenterol 2021;:101766. [PMID: 34332137 DOI: 10.1016/j.clinre.2021.101766] [Reference Citation Analysis]
156 Yao S, Ye Z, Wei Y, Jiang HY, Song B. Radiomics in hepatocellular carcinoma: A state-of-the-art review. World J Gastrointest Oncol 2021; 13(11): 1599-1615 [PMID: 34853638 DOI: 10.4251/wjgo.v13.i11.1599] [Reference Citation Analysis]
157 Navin PJ, Venkatesh SK. Hepatocellular Carcinoma: State of the Art Imaging and Recent Advances. J Clin Transl Hepatol 2019;7:72-85. [PMID: 30944823 DOI: 10.14218/JCTH.2018.00032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
158 Joo I, Lee JM, Lee DH, Jeon JH, Han JK. Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features? Eur Radiol 2019;29:1724-32. [PMID: 30255250 DOI: 10.1007/s00330-018-5727-1] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 10.5] [Reference Citation Analysis]
159 Lee YT, Wang JJ, Zhu Y, Agopian VG, Tseng HR, Yang JD. Diagnostic Criteria and LI-RADS for Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2021;17:409-13. [PMID: 34386205 DOI: 10.1002/cld.1075] [Reference Citation Analysis]
160 Burti S, Zotti A, Contiero B, Banzato T. Computed tomography features for differentiating malignant and benign focal liver lesions in dogs: A meta-analysis. Vet J 2021;278:105773. [PMID: 34742915 DOI: 10.1016/j.tvjl.2021.105773] [Reference Citation Analysis]
161 Zech CJ, Ba-Ssalamah A, Berg T, Chandarana H, Chau GY, Grazioli L, Kim MJ, Lee JM, Merkle EM, Murakami T, Ricke J, B Sirlin C, Song B, Taouli B, Yoshimitsu K, Koh DM. Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol 2020;30:370-82. [PMID: 31385048 DOI: 10.1007/s00330-019-06369-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
162 Wei Y, Gong J, He X, Liu B, Liu T, Yang S, Zhou Z, Liang L, Zhan S, Xia Z, Duan G, Lin B, Han Q, Li S, Qin W, Pickhardt PJ, Deng D. An MRI-Based Radiomic Model for Individualized Prediction of Hepatocellular Carcinoma in Patients With Hepatitis B Virus-Related Cirrhosis. Front Oncol 2022;12:800787. [DOI: 10.3389/fonc.2022.800787] [Reference Citation Analysis]
163 Jiang H, Song B, Qin Y, Wei Y, Konanur M, Wu Y, Zaki IH, McInnes MDF, Lafata KJ, Bashir MR. Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity. J Magn Reson Imaging 2021. [PMID: 34236120 DOI: 10.1002/jmri.27824] [Reference Citation Analysis]
164 Kornberg A, Schernhammer M, Kornberg J, Friess H, Thrum K. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma. Dig Dis Sci 2019;64:269-80. [PMID: 30259282 DOI: 10.1007/s10620-018-5296-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
165 Roth CG, Marzio DH, Guglielmo FF. Contributions of Magnetic Resonance Imaging to Gastroenterological Practice: MRIs for GIs. Dig Dis Sci 2018;63:1102-22. [PMID: 29549474 DOI: 10.1007/s10620-018-4991-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
166 Obeidat AE, Wong LL. Spontaneous Rupture of Hepatocellular Carcinoma: New Insights. Journal of Clinical and Experimental Hepatology 2022;12:483-91. [DOI: 10.1016/j.jceh.2021.05.010] [Reference Citation Analysis]
167 Kim TH, Woo S, Han S, Suh CH, Do RKG, Lee JM. Risk Factors for Hypervascularization in Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement: A Systematic Review and Meta-analysis. Acad Radiol 2022;29:198-210. [PMID: 32962925 DOI: 10.1016/j.acra.2020.08.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
168 Jiang ST, Zhang JW, Lu X, Xu YY. Letter to the editor: Discussion on application scenario of cell-free DNA fragmentomics in primary liver cancer. Hepatology 2022. [PMID: 35334134 DOI: 10.1002/hep.32477] [Reference Citation Analysis]
169 Schobert IT, Savic LJ. Current Trends in Non-Invasive Imaging of Interactions in the Liver Tumor Microenvironment Mediated by Tumor Metabolism. Cancers (Basel) 2021;13:3645. [PMID: 34359547 DOI: 10.3390/cancers13153645] [Reference Citation Analysis]
170 Ji GW, Zhu FP, Xu Q, Wang K, Wu MY, Tang WW, Li XC, Wang XH. Machine-learning analysis of contrast-enhanced CT radiomics predicts recurrence of hepatocellular carcinoma after resection: A multi-institutional study. EBioMedicine 2019;50:156-65. [PMID: 31735556 DOI: 10.1016/j.ebiom.2019.10.057] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
171 Min JH, Kim JM, Kim YK, Kang TW, Lee SJ, Choi GS, Choi SY, Ahn S. Prospective Intraindividual Comparison of Magnetic Resonance Imaging With Gadoxetic Acid and Extracellular Contrast for Diagnosis of Hepatocellular Carcinomas Using the Liver Imaging Reporting and Data System. Hepatology 2018;68:2254-66. [PMID: 30070365 DOI: 10.1002/hep.30122] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 15.8] [Reference Citation Analysis]
172 Lachance E, Mandziuk J, Sergi CM, Bateman J, Low G. Radiologic-Pathologic Correlation of Liver Tumors. In: Sergi CM, editor. Liver Cancer. Exon Publications; 2021. pp. 87-108. [DOI: 10.36255/exonpublications.livercancer.2021.ch5] [Reference Citation Analysis]
173 Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology. 2019;156:1683-1692.e1. [PMID: 30660729 DOI: 10.1053/j.gastro.2019.01.027] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 22.0] [Reference Citation Analysis]
174 Kim T, Woo S, Han S, Suh CH, Lee DH, Lee JM. Hepatobiliary phase hypointense nodule without arterial phase hyperenhancement: are they at risk of HCC recurrence after ablation or surgery? A systematic review and meta-analysis. Eur Radiol 2020;30:1624-33. [DOI: 10.1007/s00330-019-06499-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
175 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
176 Sheng R, Huang J, Zhang W, Jin K, Yang L, Chong H, Fan J, Zhou J, Wu D, Zeng M. A Semi-Automatic Step-by-Step Expert-Guided LI-RADS Grading System Based on Gadoxetic Acid-Enhanced MRI. J Hepatocell Carcinoma 2021;8:671-83. [PMID: 34235105 DOI: 10.2147/JHC.S316385] [Reference Citation Analysis]
177 Laohawetwanit T, Wanpiyarat N, Lerttanatum N. Useful histopathologic features for diagnosing focal liver lesions with spindle cell morphology: A clinicopathologic study. Annals of Diagnostic Pathology 2022;59:151975. [DOI: 10.1016/j.anndiagpath.2022.151975] [Reference Citation Analysis]
178 Hong SB, Kim DH, Choi SH, Kim SY, Lee JS, Lee NK, Choi JI. Inadequate Ultrasound Examination in Hepatocellular Carcinoma Surveillance: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:3535. [PMID: 34441831 DOI: 10.3390/jcm10163535] [Reference Citation Analysis]
179 Bartolotta TV, Taibbi A, Midiri M, Lagalla R. Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand? Ultrasonography 2019;38:200-14. [PMID: 31006227 DOI: 10.14366/usg.18060] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
180 Lv K, Cao X, Du P, Fu JY, Geng DY, Zhang J. Radiomics for the detection of microvascular invasion in hepatocellular carcinoma. World J Gastroenterol 2022; 28(20): 2176-2183 [DOI: 10.3748/wjg.v28.i20.2176] [Reference Citation Analysis]